Abstract
Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Recent Patents on Anti-Cancer Drug Discovery
Title: Prevention and Treatment of Regimen-Related Mucosal Toxicity
Volume: 3 Issue: 2
Author(s): Joanne M. Bowen
Affiliation:
Keywords: Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral
Abstract: Current standard treatments for cancer are associated with major dose-limiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and antiinflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however rational targeting of intervention strategies to critical mechanisms will lead to further progress.
Export Options
About this article
Cite this article as:
Bowen M. Joanne, Prevention and Treatment of Regimen-Related Mucosal Toxicity, Recent Patents on Anti-Cancer Drug Discovery 2008; 3 (2) . https://dx.doi.org/10.2174/157489208784638802
DOI https://dx.doi.org/10.2174/157489208784638802 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Signal Transduction, Targeted Therapy and Cancer: From Bench to Clinics)
Current Pharmaceutical Design Bronchiolitis Obliterans Following Lung Transplantation and Stem Cell Transplantation in Pediatric Patients
Current Pediatric Reviews Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Meet the Associate Editor
MicroRNA Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Kinases as Drug Discovery Targets in Hematologic Malignancies
Current Molecular Medicine Pieces of the Complex Puzzle of Cancer Cell Energy Metabolism: An Overview of Energy Metabolism and Alternatives for Targeted Cancer Therapy
Current Medicinal Chemistry Parallel Gene Expression Profiling of Mantle Cell Lymphoma – How Do We Transform ´Omics Data into Clinical Practice
Current Genomics Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy DNA Methylation as a Target of Epigenetic Therapeutics in Cancer
Anti-Cancer Agents in Medicinal Chemistry Circumventing Immune Tolerance Through Epigenetic Modification
Current Pharmaceutical Design The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design